Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-08-07 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-08-07 English
Regulatory Filings 2025
Regulatory Filings Classification · 1% confidence The document is a 'Company Announcement' from Genmab regarding positive clinical trial results for their EPCORE FL-1 study. It details the trial's success, regulatory submission status, and implications for their drug epcoritamab. This type of corporate communication, which provides updates on clinical trial progress and regulatory milestones, is classified as a Regulatory Filing (RNS) within the provided schema, as it does not fit into specific categories like Earnings Release (which focuses on financial results) or M&A Activity.
2025-08-07 English
Legal Proceedings Report 2025
Legal Proceedings Report Classification · 1% confidence The document is a press release from Genmab announcing positive clinical trial results (Phase 3 EPCORE FL-1) and regulatory updates regarding a supplemental Biologics License Application (sBLA). It is a standard corporate announcement regarding business operations and R&D progress, which falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or shareholder meeting categories.
2025-08-07 English
6-K
Foreign Filer Report
2025-07-16 English
Regulatory Filings 2025
Regulatory Filings Classification · 1% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025" and provides specific financial figures (Net sales of USD 3,539 million) for a recent fiscal period (Q2 2025). This structure—a brief announcement highlighting key financial metrics for a specific reporting period—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), nor is it a transcript (CT) or a presentation (IP). It is a direct release of results, not just an announcement that a report is forthcoming (RPA).
2025-07-16 English
Earnings Release 2025
Earnings Release Classification · 1% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025" and provides specific financial figures (USD 3,539 million in net sales) for a defined period (Second Quarter of 2025). This content strongly indicates an announcement of periodic financial results, focusing on key figures rather than a comprehensive report or a transcript. This aligns best with the Earnings Release (ER) definition, which covers the initial announcement of periodical financial results (key highlights only). Although it mentions the full Annual Report (Form 20-F) in the forward-looking statements disclaimer, the primary purpose of this specific document is the quarterly sales announcement, making ER the most appropriate classification. It is not a full report (10-K or IR), nor is it a presentation (IP) or a call transcript (CT). Q2 2025
2025-07-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.